Pub Date : 2025-09-01Epub Date: 2025-06-03DOI: 10.1080/03009742.2025.2503055
C Kodishala, R Jose George, R Javed, E J Lovering, C S Crowson, R J Lennon, C A Hulshizer, E Myasoedova
Objective: Several studies have reported an association between rheumatoid arthritis (RA) disease activity and the risk of Alzheimer's disease and related dementias (AD/ADRD). We examined the role of RA flares on the risk of AD/ADRD.
Method: This population-based study was conducted on an inception cohort of RA patients aged ≥ 50 years, who were residents of Minnesota, USA (1988-2014). RA-related flare/remission status was ascertained via medical record review. In definition 1, flares were considered to start on the day of documentation and resolve halfway to the next visit. In definition 2, 'acute flares' were defined as lasting for 6 weeks. Incident dementia was defined by the presence of two ICD-9/10 codes for AD/ADRD ≥ 30 days apart. Cox models were used to assess the association of RA flares with AD/ADRD.
Results: We included 774 patients with RA. During a median follow-up of 7.8 years, 79 patients (10%) developed AD/ADRD. During a total of 12 437 medical visits, patients were flaring at 3407 visits (27.4%) and in remission at 2900 visits (23.3%). Using definition 1, we found no significant evidence of a higher risk of incident AD/ADRD when in RA flare versus remission [hazard ratio (HR) 1.11, 95% confidence interval (CI) 0.63-1.96]. Using definition 2, patients with RA flare had an estimated 1.8-fold increased risk of AD/ADRD (HR 1.82, 95% CI 0.82-4.06) versus remission, which was not statistically significant.
Conclusion: We found that RA flares are common. A detrimental effect of active flares on cognitive status cannot be excluded.
目的:一些研究报道了类风湿性关节炎(RA)疾病活动性与阿尔茨海默病和相关痴呆(AD/ADRD)风险之间的关联。我们研究了RA耀斑在AD/ADRD风险中的作用。方法:这项基于人群的研究是在美国明尼苏达州(1988-2014)年龄≥50岁的RA患者中进行的。通过医疗记录审查确定ra相关的发作/缓解状态。在定义1中,耀斑被认为在记录当天开始,并在下一次访问的中途消失。定义2中,“急性发作”定义为持续6周。偶发性痴呆的定义是AD/ADRD间隔≥30天出现两个ICD-9/10代码。采用Cox模型评估RA耀斑与AD/ADRD的关系。结果:我们纳入了774例RA患者。在中位7.8年的随访期间,79名患者(10%)发展为AD/ADRD。在总共12437次就诊中,患者在3407次就诊中出现症状(27.4%),在2900次就诊中缓解(23.3%)。使用定义1,我们没有发现明显的证据表明RA发作与缓解时AD/ADRD发生的风险更高[风险比(HR) 1.11, 95%可信区间(CI) 0.63-1.96]。使用定义2,与缓解相比,RA发作患者AD/ADRD的风险估计增加1.8倍(HR 1.82, 95% CI 0.82-4.06),这没有统计学意义。结论:我们发现RA耀斑是常见的。不能排除活动耀斑对认知状态的有害影响。
{"title":"Role of rheumatoid arthritis flare in the risk of Alzheimer's disease and related dementias: a population-based cohort study.","authors":"C Kodishala, R Jose George, R Javed, E J Lovering, C S Crowson, R J Lennon, C A Hulshizer, E Myasoedova","doi":"10.1080/03009742.2025.2503055","DOIUrl":"10.1080/03009742.2025.2503055","url":null,"abstract":"<p><strong>Objective: </strong>Several studies have reported an association between rheumatoid arthritis (RA) disease activity and the risk of Alzheimer's disease and related dementias (AD/ADRD). We examined the role of RA flares on the risk of AD/ADRD.</p><p><strong>Method: </strong>This population-based study was conducted on an inception cohort of RA patients aged ≥ 50 years, who were residents of Minnesota, USA (1988-2014). RA-related flare/remission status was ascertained via medical record review. In definition 1, flares were considered to start on the day of documentation and resolve halfway to the next visit. In definition 2, 'acute flares' were defined as lasting for 6 weeks. Incident dementia was defined by the presence of two ICD-9/10 codes for AD/ADRD ≥ 30 days apart. Cox models were used to assess the association of RA flares with AD/ADRD.</p><p><strong>Results: </strong>We included 774 patients with RA. During a median follow-up of 7.8 years, 79 patients (10%) developed AD/ADRD. During a total of 12 437 medical visits, patients were flaring at 3407 visits (27.4%) and in remission at 2900 visits (23.3%). Using definition 1, we found no significant evidence of a higher risk of incident AD/ADRD when in RA flare versus remission [hazard ratio (HR) 1.11, 95% confidence interval (CI) 0.63-1.96]. Using definition 2, patients with RA flare had an estimated 1.8-fold increased risk of AD/ADRD (HR 1.82, 95% CI 0.82-4.06) versus remission, which was not statistically significant.</p><p><strong>Conclusion: </strong>We found that RA flares are common. A detrimental effect of active flares on cognitive status cannot be excluded.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"331-338"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-07-18DOI: 10.1080/03009742.2025.2524950
Y Ding, L Jia, L Zhou
{"title":"Anti-synthetase syndrome with fungal infection and viral encephalitis: a case report.","authors":"Y Ding, L Jia, L Zhou","doi":"10.1080/03009742.2025.2524950","DOIUrl":"10.1080/03009742.2025.2524950","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"392-394"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-05-21DOI: 10.1080/03009742.2025.2497606
S F Ling, P Ho, M Bukhari, D Mewar, H Chinoy, A W Morgan, J D Isaacs, A G Wilson, K L Hyrich, A Barton, D Plant
Objective: Previous publications have reported that increased absolute monocyte counts are associated with treatment non-response in patients with rheumatoid arthritis (RA). This study investigated whether full blood count (FBC) components from routine clinical testing before treatment with a biological disease-modifying anti-rheumatic drug (bDMARD) were associated with treatment non-response after 6 months of treatment.
Method: From a UK-based prospective multicentre study of patients with RA starting a bDMARD, data from 246 patients attending five of the participating centres were retrieved. FBC components were analysed for their association with European Alliance of Associations for Rheumatology non-response after 6 months of treatment using backward stepwise logistic regression, adjusting for potential confounders. Final models underwent resampling with 200 repeats of out-of-bag bootstrapping to assess model performance using area under the receiver operating characteristics (AUROC) curves. Model fit was compared using the Akaike information criterion (AIC).
Results: After 6 months of treatment, the only FBC component predictive of non-response was pretreatment absolute monocyte count [adjusted odds ratio (ORadj) 9.56, 95% confidence intervals (CI) 1.61-59.86, p = 0.01, AUROC = 60.42%). The model including monocytes as a predictor demonstrated superior performance to the covariates-only model (AIC 184.36 vs 188.51, respectively).
Conclusion: In the largest study to date, increasing absolute monocyte counts were associated with bDMARD non-response after 6 months of treatment, replicating previous reports. Validation and mechanistic studies are required to inform future treatment selection.
目的:以前的出版物报道了绝对单核细胞计数增加与类风湿关节炎(RA)患者治疗无反应相关。本研究调查了使用生物疾病缓解抗风湿药物(bDMARD)治疗前常规临床检测的全血细胞计数(FBC)成分是否与治疗6个月后治疗无反应相关。方法:从一项基于英国的RA患者开始bDMARD的前瞻性多中心研究中,检索了来自5个参与中心的246名患者的数据。使用后向逐步逻辑回归分析FBC成分与欧洲风湿病协会联盟治疗6个月后无反应的关系,调整潜在混杂因素。最终的模型进行了200次袋外自举的重新采样,利用接受者操作特征(AUROC)曲线下的面积来评估模型的性能。采用赤池信息准则(Akaike information criterion, AIC)对模型拟合进行比较。结果:治疗6个月后,唯一预测无反应的FBC成分是预处理绝对单核细胞计数[调整优势比(ORadj) 9.56, 95%可信区间(CI) 1.61 ~ 59.86, p = 0.01, AUROC = 60.42%]。包括单核细胞作为预测因子的模型表现出优于仅协变量模型的性能(AIC分别为184.36和188.51)。结论:在迄今为止最大规模的研究中,在治疗6个月后,增加的绝对单核细胞计数与bDMARD无反应相关,重复了先前的报道。需要验证和机制研究来为未来的治疗选择提供信息。
{"title":"Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritis.","authors":"S F Ling, P Ho, M Bukhari, D Mewar, H Chinoy, A W Morgan, J D Isaacs, A G Wilson, K L Hyrich, A Barton, D Plant","doi":"10.1080/03009742.2025.2497606","DOIUrl":"10.1080/03009742.2025.2497606","url":null,"abstract":"<p><strong>Objective: </strong>Previous publications have reported that increased absolute monocyte counts are associated with treatment non-response in patients with rheumatoid arthritis (RA). This study investigated whether full blood count (FBC) components from routine clinical testing before treatment with a biological disease-modifying anti-rheumatic drug (bDMARD) were associated with treatment non-response after 6 months of treatment.</p><p><strong>Method: </strong>From a UK-based prospective multicentre study of patients with RA starting a bDMARD, data from 246 patients attending five of the participating centres were retrieved. FBC components were analysed for their association with European Alliance of Associations for Rheumatology non-response after 6 months of treatment using backward stepwise logistic regression, adjusting for potential confounders. Final models underwent resampling with 200 repeats of out-of-bag bootstrapping to assess model performance using area under the receiver operating characteristics (AUROC) curves. Model fit was compared using the Akaike information criterion (AIC).</p><p><strong>Results: </strong>After 6 months of treatment, the only FBC component predictive of non-response was pretreatment absolute monocyte count [adjusted odds ratio (OR<sub>adj</sub>) 9.56, 95% confidence intervals (CI) 1.61-59.86, p = 0.01, AUROC = 60.42%). The model including monocytes as a predictor demonstrated superior performance to the covariates-only model (AIC 184.36 vs 188.51, respectively).</p><p><strong>Conclusion: </strong>In the largest study to date, increasing absolute monocyte counts were associated with bDMARD non-response after 6 months of treatment, replicating previous reports. Validation and mechanistic studies are required to inform future treatment selection.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"325-330"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-06-03DOI: 10.1080/03009742.2025.2503054
C Hyldgaard, A R Pedersen, T Ellingsen, E Bendstrup
Objective: Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA). The aim of this study was to compare pulmonary function trajectories in RA-ILD, focusing on the impact of oral corticosteroid therapy and radiographic pattern.
Method: We used a multiple regression model with line artime trend and individual random coefficients for intercept and slope to assess forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), allowing the description of individual linear patterns and systematic differences at a group level.
Results: We included 101 patients with RA-ILD retrospectively. Mean FVC and DLCO were lower in patients who received corticosteroid therapy for ILD than in untreated patients (79% vs 95% predicted, and 48% vs 58% predicted). The change in FVC per 30 days was -0.10 [95% confidence interval (95% CI) -0.18; -0.04] in the treated and -0.13 (95% 20 CI -0.19; -0.07) in the untreated group. The between-group difference was not significant (-0.03, 95% CI -0.12; 0.06, p = 0.571). For DLCO, the change per 30 days was -0.10 (95% CI -0.15; -0.04) in the treated and -0.10 (95% CI -0.14; -0.05) in the untreated group, with no significant between-group difference (0.0007, 95% CI -0.07; 0.07, p = 0.985). Inclusion of radiographic pattern did not change the results.
Conclusion: The rate of pulmonary function decline was similar for corticosteroid-treated and untreated patients, although treated patients had significantly lower pulmonary function. This may indicate a limited disease-modifying effect in RA-ILD, but further studies are needed.
目的:间质性肺疾病(ILD)是类风湿关节炎(RA)的严重并发症。本研究的目的是比较RA-ILD的肺功能轨迹,重点关注口服皮质类固醇治疗和影像学表现的影响。方法:采用具有线性时间趋势和截距和斜率的个体随机系数的多元回归模型来评估肺的强制肺活量(FVC)和一氧化碳弥散量(DLCO),允许在组水平上描述个体线性模式和系统差异。结果:我们回顾性纳入101例RA-ILD患者。接受皮质类固醇治疗的ILD患者的平均FVC和DLCO低于未接受治疗的患者(79% vs 95%预测,48% vs 58%预测)。每30天FVC的变化为-0.10[95%置信区间(95% CI) -0.18;治疗组为-0.04],对照组为-0.13 (95% 20 CI -0.19;-0.07)。组间差异无统计学意义(-0.03,95% CI -0.12;0.06, p = 0.571)。对于DLCO,每30天的变化为-0.10 (95% CI -0.15;治疗组为-0.04),治疗组为-0.10 (95% CI -0.14;-0.05),组间差异无统计学意义(0.0007,95% CI -0.07;0.07, p = 0.985)。纳入x线影像没有改变结果。结论:皮质类固醇治疗组与未治疗组肺功能下降率相似,但治疗组肺功能明显降低。这可能表明RA-ILD的疾病改善作用有限,但需要进一步研究。
{"title":"Pulmonary function trajectories in rheumatoid arthritis-associated interstitial lung disease.","authors":"C Hyldgaard, A R Pedersen, T Ellingsen, E Bendstrup","doi":"10.1080/03009742.2025.2503054","DOIUrl":"10.1080/03009742.2025.2503054","url":null,"abstract":"<p><strong>Objective: </strong>Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA). The aim of this study was to compare pulmonary function trajectories in RA-ILD, focusing on the impact of oral corticosteroid therapy and radiographic pattern.</p><p><strong>Method: </strong>We used a multiple regression model with line artime trend and individual random coefficients for intercept and slope to assess forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), allowing the description of individual linear patterns and systematic differences at a group level.</p><p><strong>Results: </strong>We included 101 patients with RA-ILD retrospectively. Mean FVC and DLCO were lower in patients who received corticosteroid therapy for ILD than in untreated patients (79% vs 95% predicted, and 48% vs 58% predicted). The change in FVC per 30 days was -0.10 [95% confidence interval (95% CI) -0.18; -0.04] in the treated and -0.13 (95% 20 CI -0.19; -0.07) in the untreated group. The between-group difference was not significant (-0.03, 95% CI -0.12; 0.06, p = 0.571). For DLCO, the change per 30 days was -0.10 (95% CI -0.15; -0.04) in the treated and -0.10 (95% CI -0.14; -0.05) in the untreated group, with no significant between-group difference (0.0007, 95% CI -0.07; 0.07, p = 0.985). Inclusion of radiographic pattern did not change the results.</p><p><strong>Conclusion: </strong>The rate of pulmonary function decline was similar for corticosteroid-treated and untreated patients, although treated patients had significantly lower pulmonary function. This may indicate a limited disease-modifying effect in RA-ILD, but further studies are needed.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"339-345"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-06-18DOI: 10.1080/03009742.2025.2503062
E Hulander, M Hallström, C Feldthusen, E Klingberg, J Beckman Rehnman, M Geijer, T Zverkova Sandström, S Söderberg, A Deminger, H Forsblad-d'Elia
Objectives: This study aimed to assess the relationship between dietary intake and disease outcomes in patients with radiographic axial spondyloarthritis (r-axSpA), focusing on inflammation and disease activity, while also evaluating other health outcomes, and to compare dietary intake between patients and controls.
Method: In a cross-sectional analysis, we studied 295 patients with r-axSpA (modified New York criteria for ankylosing spondylitis) in northern and south-western Sweden. Of these, 155 were of similar age to controls (50-64 years) from the Swedish CArdioPulmonary bioImage Study (SCAPIS) and were matched on sex, age, and geographical location to 604 controls. Dietary intake was evaluated using the MiniMealQ food frequency questionnaire. Differences in dietary intake between patients and controls were assessed in conditional logistic regression models. Nutrients with significant group differences were examined in patients (n = 295) by regression models for the outcomes Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (ASDAS) and CRP.
Results: Patients had a lower dietary fibre density, as well as lower intake of marine omega-3 fatty acids, calcium, folate, iodine, phosphorus, potassium, selenium, vitamins A, C, and K, β-carotene, and alcohol. Low intake of marine omega-3 fatty acids was associated with a higher ASDAS, and a lower dietary fibre density was associated with elevated CRP.
Conclusions: Patients with r-axSpA report lower dietary quality compared with controls. Dietary intake is related to disease activity and inflammation. Further exploration of metabolic biomarkers and disease outcomes is warranted, and the impact of a health-promoting dietary intervention should be assessed.
{"title":"Dietary intake is related to disease activity and inflammation in radiographic axial spondyloarthritis: a cross-sectional multi-regional study.","authors":"E Hulander, M Hallström, C Feldthusen, E Klingberg, J Beckman Rehnman, M Geijer, T Zverkova Sandström, S Söderberg, A Deminger, H Forsblad-d'Elia","doi":"10.1080/03009742.2025.2503062","DOIUrl":"10.1080/03009742.2025.2503062","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the relationship between dietary intake and disease outcomes in patients with radiographic axial spondyloarthritis (r-axSpA), focusing on inflammation and disease activity, while also evaluating other health outcomes, and to compare dietary intake between patients and controls.</p><p><strong>Method: </strong>In a cross-sectional analysis, we studied 295 patients with r-axSpA (modified New York criteria for ankylosing spondylitis) in northern and south-western Sweden. Of these, 155 were of similar age to controls (50-64 years) from the Swedish CArdioPulmonary bioImage Study (SCAPIS) and were matched on sex, age, and geographical location to 604 controls. Dietary intake was evaluated using the MiniMealQ food frequency questionnaire. Differences in dietary intake between patients and controls were assessed in conditional logistic regression models. Nutrients with significant group differences were examined in patients (n = 295) by regression models for the outcomes Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (ASDAS) and CRP.</p><p><strong>Results: </strong>Patients had a lower dietary fibre density, as well as lower intake of marine omega-3 fatty acids, calcium, folate, iodine, phosphorus, potassium, selenium, vitamins A, C, and K, β-carotene, and alcohol. Low intake of marine omega-3 fatty acids was associated with a higher ASDAS, and a lower dietary fibre density was associated with elevated CRP.</p><p><strong>Conclusions: </strong>Patients with r-axSpA report lower dietary quality compared with controls. Dietary intake is related to disease activity and inflammation. Further exploration of metabolic biomarkers and disease outcomes is warranted, and the impact of a health-promoting dietary intervention should be assessed.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"346-355"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-11DOI: 10.1080/03009742.2025.2527452
L Jia, L Zhou, Y Y Ding, X Zhang
{"title":"Case report: brucellosis with fever and eye pain as first symptoms.","authors":"L Jia, L Zhou, Y Y Ding, X Zhang","doi":"10.1080/03009742.2025.2527452","DOIUrl":"10.1080/03009742.2025.2527452","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"395-397"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-03-12DOI: 10.1080/03009742.2025.2471717
S Gülle, D Şanlı
{"title":"A rare and striking case of capillary leak syndrome.","authors":"S Gülle, D Şanlı","doi":"10.1080/03009742.2025.2471717","DOIUrl":"10.1080/03009742.2025.2471717","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"385-386"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-06-02DOI: 10.1080/03009742.2025.2503573
S J Rahbek, C Tandrup Nielsen, J Lindhardsen, M Mogensen, L P Diederichsen
{"title":"Anifrolumab for refractory dermatomyositis: a case series.","authors":"S J Rahbek, C Tandrup Nielsen, J Lindhardsen, M Mogensen, L P Diederichsen","doi":"10.1080/03009742.2025.2503573","DOIUrl":"10.1080/03009742.2025.2503573","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"387-389"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-04-02DOI: 10.1080/03009742.2025.2480871
C B Mukhtyar, A Ather, G Ducker, T Ecclestone, S Fordham, H Naeem, F L Coath
Objective: Ultrasonography has been proposed as the initial diagnostic modality in suspected giant cell arteritis. Proposed quality standards advocate for a certified sonographer. Currently, there are no formal training programmes, and single educational events do not suffice as certification. We developed a preceptorship programme for diagnostic ultrasonography. Here, we describe its contents and test its efficacy.
Method: The programme comprises three stages. The preclinical stage includes machine setting and surface anatomy. Second stage includes supervised assessment, passed via a directly observed procedure form. In the final validation stage, the trainee and trainer perform an ultrasonography examination in succession, with a comparison of the results. For this programme, a scan included all three segments of the superficial temporal artery and all three parts of the axillary arteries. Comparison of the intima-media thickness (IMT) and categorical judgements for the halo sign and final diagnosis were made.
Results: Six trainees have been through this programme so far. A median of 16 ultrasonography examinations was required to reach the validation stage. The mean ± SD IMT in 360 segments, as measured by the trainee and trainer, was 0.45 ± 0.34 and 0.46 ± 0.35, respectively (p = 0.26). The agreement between trainee and trainer for the presence or absence of halo was excellent in 403 segments (κ = 0.91, 95% confidence interval 0.86, 0.96). There was 100% agreement on the final diagnosis.
Conclusion: The integration of technical knowledge with practical skills results in a robust training programme, validating trainees to continue scanning independently.
{"title":"A preceptorship programme to learn ultrasonography for diagnosis of giant cell arteritis.","authors":"C B Mukhtyar, A Ather, G Ducker, T Ecclestone, S Fordham, H Naeem, F L Coath","doi":"10.1080/03009742.2025.2480871","DOIUrl":"10.1080/03009742.2025.2480871","url":null,"abstract":"<p><strong>Objective: </strong>Ultrasonography has been proposed as the initial diagnostic modality in suspected giant cell arteritis. Proposed quality standards advocate for a certified sonographer. Currently, there are no formal training programmes, and single educational events do not suffice as certification. We developed a preceptorship programme for diagnostic ultrasonography. Here, we describe its contents and test its efficacy.</p><p><strong>Method: </strong>The programme comprises three stages. The preclinical stage includes machine setting and surface anatomy. Second stage includes supervised assessment, passed via a directly observed procedure form. In the final validation stage, the trainee and trainer perform an ultrasonography examination in succession, with a comparison of the results. For this programme, a scan included all three segments of the superficial temporal artery and all three parts of the axillary arteries. Comparison of the intima-media thickness (IMT) and categorical judgements for the halo sign and final diagnosis were made.</p><p><strong>Results: </strong>Six trainees have been through this programme so far. A median of 16 ultrasonography examinations was required to reach the validation stage. The mean ± SD IMT in 360 segments, as measured by the trainee and trainer, was 0.45 ± 0.34 and 0.46 ± 0.35, respectively (p = 0.26). The agreement between trainee and trainer for the presence or absence of halo was excellent in 403 segments (κ = 0.91, 95% confidence interval 0.86, 0.96). There was 100% agreement on the final diagnosis.</p><p><strong>Conclusion: </strong>The integration of technical knowledge with practical skills results in a robust training programme, validating trainees to continue scanning independently.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"356-361"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}